MedTrace Logo

Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive Disorder

NCT00807248 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 490

Last updated 2012-12-17

Study results available
· View outcomes & findings →

Summary

To compare the efficacy of escitalopram fixed dose 20 mg/day in combination with fixed doses of gaboxadol (5 and 10 mg/day) versus escitalopram fixed dose 20 mg/day after 8 weeks of treatment in patients with Major Depressive Disorder

Conditions

Interventions

DRUG

Escitalopram placebo

Once daily before bedtime for 8 weeks

DRUG

Gaboxadol placebo

Once daily before bedtime for 8 weeks

DRUG

Escitalopram 20 mg

Once daily before bedtime for 8 weeks

DRUG

Gaboxadol 5 mg

Once daily before bedtime for 8 weeks

DRUG

Gaboxadol 10 mg

Once daily before bedtime for 8 weeks

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2009-12-31
Completion
2010-02-28

Countries

  • Austria
  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00807248 on ClinicalTrials.gov